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Abstract. Objective: The lack of overt signs and symptoms and controversies surrounding the thyroid
stimulating hormone (TSH) reference range variability make the management of subclinical hypothyroidism
(sHT) a challenge. Because muscle cramps and weakness have been noted in sHT, histological skeletal mus-
cle examination may be of diagnostic significance as the presence of abnormalities would substantiate a sig-
nificant consequence of the mild thyroid failure presumed to be present in the individual with sHT. The
objective of this study was to investigate the ultrastructural and histological changes of skeletal muscle as-
sociated with sHT.
Design: Skeletal muscle biopsies from the vastus lateralis were obtained from four subjects with sHT.
Samples were fixed, sectioned, and stained for quantitative and qualitative electron and light microscopic
analysis.
Main Outcome: Analyses revealed characterizable morphological and ultrastructural alterations and
quantitative mitochondrial variations between subjects, indicative of skeletal muscle mitochondrial dysfunc-
tion in sHT patients. For the 4 subjects, mean mitochondrial perimeter (MP) was 1.09  ± 0.312 ì, mean
mitochondrial area (MA) was 0.10 ± 0.05 ì², and mean mitochondrial volume density was 1.92  ± 0.95. 
Conclusions: The observed and quantified mitochondrial alterations and the noted morphological and
ultrastructural alterations identify previously undocumented pathological skeletal muscle alterations asso-
ciated with sHT. The observed morphological and ultrastructural alterations lend support to a trend of  pro-
gression of sHT into overt hypothyroidism as a result of mitochondrial dysfunction and associated metabolic
shift. The identification of these skeletal muscle alterations as sequelae of sHT may lend convincing ob-
jective evidence of a pathophysiologically significant abnormality in patients with sHT. If so, this should
diminish the substantial resistance to treatment of these patients at an early stage of disease and attenuate
the progression to overt hypothyroidism.
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Introduction
Thyroid dysfunction affects more than 21 mil-
lion Americans.  Untreated thyroid dysfunction has[1]
negative health consequences, including coronary
heart disease, osteoporosis, atrial fibrillation, cogni-
tive impairment, and depression. When analyzed as
a whole, these negative health consequences result-
ing directly from untreated thyroid dysfunction are
among the nation’s largest causes of morbidity, mor-
tality, and diminished quality of daily life in older
adults.  The incidence of diagnosed hypothyroidism[1]
ranges from 4% to 8.5%.  Subclinical hypothyroid-[2]
ism is more common in women over the age of 60,
(20%)  and males $ 65 years.  [2] [2,3]
Subclinical hypothyroidism represents the earli-
est stage of thyroid hypofunction.  It is diagnosed[4]
by an elevation of serum thyroid-stimulating hor-
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4 4ference range serum free T  (FT ) level of 0.8-2.3
ng/dL.  The rate of progression from subclinical[4]
hypothyroidism to overt hypothyroidism directly cor-
relates with the patient’s initial TSH value,  and[2]
most experts recommend treatment of subclinical
hypothyroidism when TSH values exceed 10 mIU/L.
However, 75% of those diagnosed with subclinical
hypothyroidism have TSH values in the 5-10 mIU/L
range, thereby creating an imprecise barometer re-[5] 
garding the need to and recommendations for the
initiation of thyroid hormone treatment.
Typical signs and symptoms of overt hypothy-
roidism include cold intolerance, dry skin, constipa-
tion, depression, myalgia, arthralgia, cramps, and
weakness as well as altered metabolic parameters
including increased total and LDL cholesterol.  Ad-[1]
ding to the difficulty in diagnosis, subclinical hy-
pothyroid patients may not present with consistent
symptoms. Since myalgia, muscle cramps, and
weakness have been reported in subclinical hypo-
thyroidism,  a histological examination of skeletal[6]
muscle in patients with subclinical hypothyroidism
would be important in confirming a physical con-
sequence of subclinical hypothyroidism. However,
no literature exists describing the ultrastructural
morphological characteristics of skeletal muscle in
subclinical hypothyroidism patients.
The purpose of this study was to examine biop-
sied skeletal muscle of 4 clinically diagnosed sub-
clinical hypothyroid patients and identify ultrastruc-
tural and morphological characteristics, specifically
mitochondrial alterations, found in  the subclinical
hypothyroid patients.
Materials and Methods
Subjects. Four patients served as study sub-
jects. Each patient's informed consent for these pro-
cedures was obtained as part of the Institutional
Review Board (Lifespan Academic Medical Center)
approval process. A comprehensive physical exam-
ination and medical history review were included in
the patients screening. Patients were included if they
were ages 21-80 years, had no prior history of hor-
mone supplements in the preceding six months, and
4had elevated TSH levels with FT  levels within ref-
erence range.
Patient 1.  A 34 year old female weighing 76.7
kg (169.1 lbs) with no family history of thyroid dys-
function presented with a TSH level of 14.33 m
4IU/L and a FT  level of 0.84 ng/dL (Table 1). The
patient presented with a weight gain $ 6.8 kg (14.99
lbs) over the course of the previous year, cold intol-
erance and low energy levels characterized by mus-
cle weakness, myalgia, and muscle spasms exacer-
bated by cold exposure and alopecia. Her sleep pat-
tern and bowel function were normal. At the time of
her presentation, she was treated only with an oral
contraceptive.
Patient 2. A 46 year old male weighing 78.0 kg
(172.0 lbs) with no family history of thyroid dys-
function, presented with a TSH level of 15.2 mIU/L
4and a FT  level of 0.86 ng/dL (Table 1). He was not
on medication at the time of evaluation. Review of
systems revealed no decrease in energy level as
measured by physical performance, normal sleeping
patterns, no weight change within the last year, no
reported muscle weakness, spasm or myalgia and no
perceptible intolerance to cold. Bowel movements
were normal and there was no evidence of alopecia.
Patient 3.  A 49 year old male weighing 83.5 kg
(184.1 lbs) with a positive family history of thyroid
dysfunction presented with a TSH of 5.5 m IU/L and
4FT  level of 1.03 ng/dL (Table 1). His medications at
presentation included Lovastatin, niacin, Metoprolol,
Clopidogrel, ASA, and Ramipril. He reported a se-
vere lack of energy characterized by a decrease in
physical performance. He reported no weight gain,
no muscle weakness, spasm or pain, and no percep-
tible increase in cold intolerance. His bowel function
was normal  and no  alopecia was noted. 
Patient 4. A 44 year old male weighing 70.8 kg
(156.1 lbs) with a history of Graves’ Disease. He was
not on medication and presented with a TSH level of
411.01 m IU/L and a FT  level of 0.80 ng/dL (Table
1). He reported a loss of energy, a significant weight
4Table 1. TSH, FT  Levels and Clinical Symptoms of 4
Patients with Subclinical Hypothyroidism.
4Patient TSH (mIU/L) FT  (ng/dL)
Clinical
Symptoms*
1 14.3 0.84 E, W , MW , P, MP,
MS, CI, H
2 15.2 0.86
3 5.5 1.03 E, P
4 11 0.8 E, S, W , MW , P,
MP. MS, H
*Decreased energy level (E), abnormal sleep pattern (S),
increased weight (W), muscle weakness (MW), decreased
physical performance (P), muscle pain (MP), muscle spasm (MS),
cold intolerance (CI), and hair loss (H).
Dunn, M.E., et al.: Muscle Mitochondrial Dysfunction . . . Subclinical Hypothyroidism.   Thyroid Science 4(5):CR1-8, 2009   3
gain of $ 6.8 kg (15 lbs) within the previous year,
alopecia, and generalized muscular weakness in his
arms, legs, and back. He also complained of recur-
rent and localized back pain.
Blood Measurements. Blood samples were then
4taken to identify TSH and FT  levels to confirm the
presence of subclinical hypothyroidism (Table 1).
Patients were instructed to refrain from nonsteroidal
anti-inflammatory drugs (NSAIDS) for 5 days prior
to biopsy.
Muscle Biopsy Procedure. Biopsied samples
were taken from the vastus lateralis muscle, 25 cm
proximal to the tibial tuberosity and 5 cm lateral to
the midline of the femur from each of the 4 pa-
tients.  The tissue was immediately placed in cold[7]
(4°C [39.2°F]) paraformaldehyde and 1.4% gluter-
aldehyde in 0.1M sodium cacodylate buffer. The
tissue was cubed for light and electron microscopic
evaluation and post fixed in osmium tetroxide in so-
dium cacodylate buffer. Following buffer rinses and
dehydration in ethanol and propylene oxide, the tis-
sues were flat embedded in Epon 812 and placed in
a 70°C (158°F) oven to polymerize for 48-hours.
Thick and ultrathin sections were cut using a Dupont
Sorval MT2B ultramicrotome and prepared for light
and electron microscopic analysis using standard
procedures.[8]
Morphological Analyses. Qualitative light mi-
croscopy was performed using an Olympus BX51
light microscope with an Olympus DP11 digital cam-
era. Digital images were analyzed using Image J and
NIH Image analysis software. Electron microscopic
examination was performed using a Philips 301
transmission electron microscope (TEM) equipped
with an Advanced Microscopy Techniques image
capturing system at magnifications from 4,500x to
45,000x, allowing for a more expansive examination
of the muscle fiber. 
Quantitative mitochondrial analysis was per-
formed using Media Cybernetics, Inc. (Silver
Springs, MD) Image-Pro Express image analysis
software. Digital images were captured using a 1024
x 768 capture resolution setting using the Lumenera
Scientific Infinity 2 side-column mounted digital
camera. Each digital micrograph was then analyzed
using the Image-Pro Express software. 
A grating replica calibration grid (Electron Mi-
croscopy Services, Hatfield, PA) in conjunction with
a Photomicrographic Scale Marker (Dunn and
Reidman, Pacific Palisades, CA) were used to cal-
ibrate the determined perimeter of each mitochon-
drion and to convert measurements from pixels to
micrometers (ì). Ten captured electron micrographs
per subject, each taken from different fibers, were
analyzed to determine mitochondrial perimeter (MP).
Mitochondrial area (MA) was calculated as a func-
tion of perimeter. Mitochondrial volume density was
Table 2. Mitochondrial morphometric data of 4 subclinical hypothyroidism patients.
Patient
Mitochondria perimeter
(MP) size range (ì)





1 0.40-0.97 0.65 ± 0.14 0.03 1.95
2 0.56-2.25 1.25 ± 0.44 0.12 0.57
3 0.57-3.34 1.11 ± 0.36 0.10 2.55
4 0.53-4.57 1.36 ± 0.52 0.15 2.6
*Mean Patient MP = 1.09 ± 0.312µ; Mean Patient MA = 0.10 ± 0.05 µ²; Mean Patient MVD = 1.92 ± 0.95% .
Figure 1. Comparison of mitochondrial area and volume
density of four subclinical hypothyroid patients.
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Mitochondrial area (MA) was calculated as a func-
tion of perimeter. Mitochondrial volume density was
measured using a 110 point lattice grid and applying
the stereological procedures of Weibel.[9]
Results
Morphological Analysis. Microscopic analysis
of skeletal muscle from these patients revealed focal
areas of marked fiber size variation and atrophy, re-
gions of myofibrillar disarray, and degeneration as
well as widened intermyofibrillar regions. Areas of
sarcolemmal blebbing, indicating a loss in membrane
integrity, thickening, and lamination of the basement
membrane were observed. Regions with occluded
capillaries and areas with distended perivascular
spaces filled with material of low electron density
containing an infiltrate of red blood cells, macro-
phages, and lymphocytes were observed. Pyknotic
nuclei as well as central nuclear migration, particu-
larly in type II atrophic fibers, as well as Z-band
streaming and disintegration, and areas devoid of
myofilaments were observed. An increased concen-
tration of glycogen aggregates and lipid deposits was
obvious, particularly in type II fibers. Reduced num-
bers of mitochondria, many with disorganized mem-
branes and cristae of unusual configurations, were
observed (Figure 2). Vesicular structures adjacent to
Z bands, intracytoplasmic inclusions, and lipofuscin
granules were observed throughout but predominant-
ly within subsarcolemmal and perinuclear regions. 
Clinical and Morphometric Analyses. TSH,
4FT , and clinical symptoms of the 4 patients are
shown in Table 1. Patients 1 and 2 had higher blood
TSH values when compared to patients 3 and 4. Al-
so, the skeletal muscle mitochondrial densities of pa-
tients 1 and 2 (Table 2) were lower when compared
with patients 3 and 4.
Mitochondrial mass per unit of muscle fiber area
is a morphological indicator of muscle oxidative ca-
pacity and can be expressed by measuring mitochon-
drial area and mitochondrial density in the same
micrograph. Figure 1 shows graphic illustrations of
mitochondrial mass per unit area of skeletal muscle
mass. This was determined by measuring mitochon-
drial volume density in combination with mean mito-
chondrial area for the 4 patients. Patients 3 and 4 had
a greater mitochondrial mass per unit area of muscle
mass than did patients 1 and 2. Smaller sized mito-
chondria were evident in the skeletal muscle of pa-
tient 1 in comparison to the other three.
Discussion
The relationship between TSH levels and clinical
symptoms in patients with subclinical hypothyroid-
ism is variable and is thus of  restricted diagnostic u-
tility. This is illustrated by the cases reported in this
study. For example, patient 2 had the highest TSH
level (15.2 m IU/L) but did not complain of myalgia
and reported no other hypothyroid symptoms (Table
1). In contrast, patient 4 complained of myalgia,
reported symptoms compatible with overt hypo-
thyroidism (Table 1), but had a lower TSH level
(11.01m IU/L). This represents an example where
morphological analysis offers a more objective meas-
urement of disease progression.
Myalgia is a consistent clinical hypothyroid
symptom and often is a precursor to a decline in
physical activity and exercise tolerance. An[10,11,12] 
early investigation of hypothyroid skeletal muscle
identified areas of normal muscle that were inter-
rupted by segments of complete structural disorgan-
ization characterized by myofilament loss.  Subse-[13]
quent studies confirmed these results and thus estab-
lished a relationship between myalgia due to overt
hypothyroidism and skeletal muscle morphological
changes.
Recognizing that specific skeletal muscle altera-
tions are typical of hypothyroid patients, we exam-
ined skeletal muscle for histological changes that oc-
cur during subclinical hypothyroidism prior to its
progression to overt hypothyroidism. We propose
that the appearance of characteristic skeletal muscle
“markers” would provide support for earlier inter-
vention and perhaps a more efficacious treatment
regimen.
Table 2 indicates that the mitochondrial mass
(mitochondrial area or mitochondrial volume densi-
ty) in 2 of our 4 patients is smaller compared to nor-
mal skeletal muscle (mitochondrial area =  0.1ì ).2 [14]
The number, size, and volume fraction of mitochon-
dria closely reflect the metabolic capacity of the or-
ganism. Therefore, our data suggest that altered skel-
etal muscle metabolism is a prominent feature in the
subclinical hypothyroid patient. 
It is interesting to note that the 2 patients with
elevated TSH levels (1 and 2) exhibited a low mito-
chondrial area per muscle fiber area (Figure 1) due to
either an unusually low mean mitochondrial area
(Patient 1 in Table 2) or a low mitochondrial volume
density (Patient 2 in Table 2). In contrast, the 2 pa-
tients with lower TSH levels had mean mitochondrial
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areas and densities closer to those for healthy adults
(range is 0.088 ì  -0.155 ì ).2 2 [15]
In an earlier study, we measured mitochondrial
area in patients with heart failure prior to (mitochon-
dria area = 0.036 ì ) and following (mitochondrial2
area = 0.046 ì ) combined aerobic and resistance2
training.  We also measured mitochondrial area in[16]
postmenopausal women at baseline (0.039 ì ) (un-2
published data). Other authors reported a mitochon-
drial area of 0.076 ì  (obese), 0.063 ì  (diabetic),2 2
and 0.114 ì  (lean adults) in muscle biopsies.  The2 [17]
mean mitochondrial area from the subclinical hypo-
thyroid patients in this study (0.10 ± 0.05 ì ) was2
within a range of 0.03 ì  to 0.15 ì  (Table 2). This2 2
indicates that although mitochondrial area in sub-
clinical hypothyroid patients did not differ greatly
Figure 2. Ultrastructural comparison of a control (a) and a subclinical 
hypothyroid patient (sHT) (b).
Fig. 2a. Control biopsy taken from an earlier unpublished study. Z bands (Z ), 
mitochondria (M) and myofilaments (Mf) show good integrity. Small black dots 
are glycogen (8) particles.
Fig. 2b. Skeletal muscle taken from patient 4. Note the damaged sarcomere 
(DS) displaying sparce myofilaments (Mf) with elongated mitochondria (M) 
spanning across the sarcomere space, once occupied by Z bands.
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from healthy adults, it did demonstrate a tendency to
decrease as TSH levels increased. The larger than
expected mean mitochondrial area in our patients
may be due to the high frequency of enlarged and
distorted mitochondria (Figure 2 and Figure 3) often
referred to as megamitochondria.  These very[16,17]
large mitochondria with low inner membrane density
may be undergoing apoptosis. However, mitochon-
drial area in the subclinical hypothyroid patients did
demonstrate a tendency to decrease as TSH levels
increased (Table 1 and Table 2), suggesting that spe-
cific mitochondrial changes in skeletal muscle are
reflective of increased TSH levels. These data are in
contrast to another investigation that reported the
presence of mitochondrial alterations only in pro-
longed clinical cases.[18]
The skeletal muscle histological profile of sub-
clinical hypothyroidism was found to include focal
areas of marked fiber variation and atrophy, regions
of myofibrillar disarray, degeneration, and central
nuclear migration, predominantly in type II fibers,
regions devoid of myofilaments, Z band streaming
and disintegration. Other studies involving overt hy-
pothyroid patients reported “cores” of myofibrillar
disarray in type I fibers, and this was observed to
correlate with the severity and duration of hypo-
thyroidism.  Increased concentrations of glyco-[19,20,21]
gen aggregates was observed in type II fibers oc-
cupying up to a  of the cross-sectional area. Therd [20] 
aggregates are thought to result from  derangements
of glycogen metabolism and to be related to the se-
verity of subclinical hypothyroidism.  These ob-[22]
servations are consistent with other reported find-
ings.  The skeletal muscle changes that char-[20,22]
acterize subclinical hypothyroidism in our report are
consistent with a previous study reporting a disease-
related metabolic shift toward anaerobic ATP pro-
duction in subclinical hypothyroidism.[24]
Mitochondrial plasticity is a response to chang-
ing metabolic conditions.  We observed re-[3,8,23,24]
duced numbers of mitochondria, many with loss of
membrane integrity, containing dense lipid inclu-
sions and cristae of unusual configurations. These
observations are consistent with previous studies of
hypothyroid patients  and lend further support[10,19,22]
to the theory that thyroid hormones have a profound
effect on mitochondrial energy expenditure.  [25]
We also found areas containing pyknotic nuclei
and central nuclear migration, consistent with severe
hypothyroid myopathy,  as well as regions demon-[26]
strating a loss in sarcolemmal integrity and bleb-
bing,  along with inflammatory cell infiltration[18,27,28]
into necrotic fiber areas. This contrasts with other
studies where necrotic muscle fibers were found in
the absence of interstitial inflammatory cells.[13]
In patients with severe hypothyroidism, selective
type II fiber atrophy was reported to be due to im-
paired glycogen utilization and accompanied by an
increased type I fiber area which gives the muscle a
“bulky” appearance.  A link between the severity[27,29]
of myopathic symptoms, the degree of type II fiber
atrophy and loss, and increased central nuclear dis-
placement has been recognized.  A correlation bet-[22]
ween clinical severity of hypothyroidism and the
degree of myofibrillar loss and abnormal glycogen
accumulation has been established.  These obser-[18]
vations are consistent with our report.
This report identifies specific skeletal muscle
morphological changes that are characteristic of
subclinical hypothyroidism. Establishing consistent
morphological markers of subclinical hypothyroid-
ism prior to disease progression could justify an
earlier, more efficacious treatment with thyroid hor-
mone. This treatment strategy may diminish mor-
bidity by preventing disease progression from sub-
clinical to overt hypothyroidism. Earlier initiation of
Figure 3. Subclinical hypothyroid patient 4.
Skeletal muscle taken from patient 4. Several mitochondria
(M) have moved from their normal position between
myofibrils (see Fig. 2) to within a sarcomere. They appear
large, elongated and irregular in shape with a lower density
of inner membranes. The curved mitochondria has lost some
internal membrane structure (8), suggesting that apoptosis
may be taking place.
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this therapy may ultimately translate into an im-
provement in patients’ lifestyle. Further research to
establish reproducibility and clinical effectiveness
appears to be warranted from these case studies.
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